Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients

Authors :: Sergio Baldari
Elisa Biasco
Matteo Salgarello
Stefano Fanti
Orazio Caffo
Pierpaolo Alongi
Gaetano Facchini
Enrico Cortesi
Viviana Frantellizzi
Eugenio Borsatti
Giuseppe De Vincentis
Fabio Monari
Roberto Bortolus
Alessandra Murabito
Angelina Filice
Clizia Zichi
Renato Costa
Salvatore Antonio Pignata
Andrea Sbrana
Massimiliano Spada
Carmine Pinto
Filippo Alongi
Marcello Tucci
Antonio Palermo
Caffo O, Frantellizzi V, Monari F, Sbrana A, Costa RP, Pinto C, Tucci M, Baldari S, Facchini G, Bortolus R, Alongi F, Alongi P, Palermo A, Fanti S, Biasco E, Murabito A, Filice A, Zichi C, Pignata S, Borsatti E, Salgarello M, Spada M, Cortesi E, Vincentis G.
Publication Year :: 2021
Publisher :: Future Medicine Ltd., 2021.
Abstract: Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p

Tools